Evidence map›Paper›PMID 20634484›Full record

ArticleCirculation. Heart failure2010

Gene delivery of sarcoplasmic reticulum calcium ATPase inhibits ventricular remodeling in ischemic mitral regurgitation.

Ronen Beeri, Miguel Chaput, J Luis Guerrero, Yoshiaki Kawase, Chaim Yosefy, Suzan Abedat, Ioannis Karakikes, Charlotte Morel, Ashley Tisosky, Suzanne Sullivan and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Circulation. Heart failure, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 66 citations in OpenAlex.

  1. Article
  2. Biologics for cardiovascular diseases: from bench to bedside.Signal transduction and targeted therapy · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Unique CaInternational journal of molecular sciences · 2018
    Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Heart Failure: Diagnosis, Management and Utilization.Journal of clinical medicine · 2016
    Review
  13. Review
  14. Mitral valve disease--morphology and mechanisms.Nature reviews. Cardiology · 2015
    Review
  15. Review
  16. Article
  17. Alterations in cardiac structure and function in a modified rat model of myocardial hypertrophy.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2014
    Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Ronen BeeriCardiac Ultrasound Laboratory and Cardiac Surgery Department, Heart Center, Massachusetts General Hospital, Boston, Mass 02114, USA.
Miguel Chaput
J Luis Guerrero
Yoshiaki Kawase
Chaim Yosefy
Suzan Abedat
Ioannis Karakikes
Charlotte Morel
Ashley Tisosky
Suzanne Sullivan
Mark D Handschumacher
Dan Gilon
Gus J Vlahakes
Roger J Hajjar
Robert A Levine
Hadassah Medical Center · IL

Funding

Effect of Mitral Regurgitation on Ischemic LV RemodelingR01HL072265 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI LEVINE, ROBERT A · 2003 to 2013
$3.5M
PICOT and Cardiac HypertrophyR01HL080498 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI HAJJAR, ROGER J. · 2006 to 2010
$2.2M
Targeting Calcium Cycling in Pre-Clinical Model CardiacR01HL083156 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI HAJJAR, ROGER J. · 2006 to 2010
$1.7M
Genetic Editing of Ca Cycling in Diabetic CardiomyopathyR01HL078731 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HAJJAR, ROGER J. · 2007 to 2010
$1.7M
ISCHEMIC MITRAL REGURGITATION: FROM MECHANISM TO THERAPYK24HL067434 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI LEVINE, ROBERT A · 2001 to 2011
$1.6M
NHLBI NIH HHS K24 HL067434NHLBI NIH HHS K24 HL67434NHLBI NIH HHS R01 HL072265NHLBI NIH HHS R01 HL 078731NHLBI NIH HHS R01 HL078731NHLBI NIH HHS R01 HL080498NHLBI NIH HHS R01 HL083156NHLBI NIH HHS R01 HL72265
6 · The paper itself

Abstract

backgroundMitral regurgitation (MR) doubles mortality after myocardial infarction (MI). We have demonstrated that MR worsens remodeling after MI and that early correction reverses remodeling. Sarcoplasmic reticulum Ca(+2)-ATPase (SERCA2a) is downregulated in this process. We hypothesized that upregulating SERCA2a might inhibit remodeling in a surgical model of apical MI (no intrinsic MR) with independent MR-type flow. METHODS AND

resultsIn 12 sheep, percutaneous gene delivery was performed by using a validated protocol to perfuse both the left anterior descending and circumflex coronary arteries with occlusion of venous drainage. We administered adeno-associated virus 6 (AAV6) carrying SERCA2a under a Cytomegalovirus promoter control in 6 sheep and a reporter gene in 6 controls. After 2 weeks, a standardized apical MI was created, and a shunt was implanted between the left ventricle and left atrium, producing regurgitant fractions of ≈30%. Animals were compared at baseline and 1 and 3 months by 3D echocardiography, Millar hemodynamics, and biopsies. The SERCA2a group had a well-maintained preload-recruitable stroke work at 3 months (decrease by 8±10% vs 42±12% with reporter gene controls; P<0.001). Left ventricular dP/dt followed the same pattern (no change vs 55% decrease; P<0.001). Left ventricular end-systolic volume was lower with SERCA2a (82.6±9.6 vs 99.4±9.7 mL; P=0.03); left ventricular end-diastolic volume, reflecting volume overload, was not significantly different (127.8±6.2 vs 134.3±9.4 mL). SERCA2a sheep showed a 15% rise in antiapoptotic pAkt versus a 30% reduction with the reporter gene (P<0.001). Prohypertrophic activated STAT3 was also 41% higher with SERCA2a than in controls (P<0.001). Proapoptotic activated caspase-3 rose >5-fold during 1 month in both SERCA2a and control animals (P=NS) and decreased by 19% at 3 months, remaining elevated in both groups.

conclusionsIn this controlled model, upregulating SERCA2a induced better function and lesser remodeling, with improved contractility, smaller volume, and activation of prohypertrophic/antiapoptotic pathways. Although caspase-3 remained activated in both groups, SERCA2a sheep had increased molecular antiremodeling "tone." We therefore conclude that upregulating SERCA2a inhibits MR-induced post-MI remodeling in this model and thus may constitute a useful approach to reduce the vicious circle of remodeling in ischemic MR.

Indexed as

Analysis of VarianceAnimalsCytomegalovirusDependovirusDisease Models, AnimalEchocardiography, Doppler, ColorGene Expression Regulation, EnzymologicGenes, ReporterGenetic TherapyGene Transfer TechniquesMaleMitral Valve InsufficiencyMyocardial IschemiaPromoter Regions, GeneticSarcoplasmic Reticulum Calcium-Transporting ATPasesSheepSarcoplasmic Reticulum Calcium-Transporting ATPases

Identifiers

PMID20634484
PMCPMC2939951
OpenAlexW2080482562

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.